Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retina Surgery Clear all

Conditions: Pseudophakia, Cataract Surgery
Interventions: Pred Forte, Lotemax; Drug
Lead sponsor: Innovative Medical; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Laguna Hills, California • Miami, Florida • Waltham, Massachusetts

Conditions: Diabetic Retinopathy
Interventions: Nepafenac ophthalmic suspension, 0.1% (NEVANAC®), Nepafenac ophthalmic suspension vehicle; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Retinoblastoma, Retinal Neoplasms
Interventions: Carboplatin, VP-16, Local Surgery, Cryotherapy, Laser hyperthermia; Drug · Procedure
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetic Retinopathy
Interventions: Aflibercept, Sham; Drug
Lead sponsor: Rishi Singh; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cystoid Macular Edema
Interventions: Standard Care, nepafenac; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 50 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Retinal Detachment, Epiretinal Membrane, Macular Hole, Fuchs Endothelial Dystrophy
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Vitrectomy
Interventions: Nepafenac, Ketorolac LS, Bromfenac; Drug
Lead sponsor: Innovative Medical; Industry
Eligibility: Not listed
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Irvine-Gass Syndrome
Interventions: Aflibercept; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Epiretinal Membrane
Interventions: Nepafenac 0.1%, BSS; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Development of Ptosis After Vitreo-retinal Surgery
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Age-Related Macular Degeneration
Interventions: Sub-retinal transplantation of MA09-hRPE cells, tacrolimus and mycophenolate mofetil, Placebo tacrolimus and mycophenolate mofetil, Sham Surgery; Biological · Drug · Procedure
Lead sponsor: Astellas Institute for Regenerative Medicine; Industry
Eligibility: 50 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cardiovascular Autonomic Neuropathy, Diabetic Autonomic Neuropathy, Autonomic Dysfunction
Interventions: ANSAR ANX 3.0 Software; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Retinitis Pigmentosa
Interventions: CAREN system training; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 25 Years to 100 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Uveitis Related Cystoid Macular Edema, Cystoid Macular Edema, Postoperative
Interventions: OCS-01; Drug
Lead sponsor: Quan Dong Nguyen; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 8
States / cities: Beverly Hills, California • Huntington Beach, California • Los Angeles, California + 5 more

Conditions: Macular Edema, Epiretinal Membrane
Interventions: Not listed
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Traction Retinal Detachments, Rhegmatogenous Retinal Detachments, Dislocated Intraocular Lens
Interventions: Intraocular assistance; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Vitreo-Retinal Surgery
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Topical Prednisolone; Drug
Lead sponsor: Patrick R. Oellers, MD; Network
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Liverpool, New York

Conditions: Retinal Diseases, Fuchs Endothelial Dystrophy, Macular Hole, Epiretinal Membrane, Retinal Detachment
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 2,911 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Retinal Detachment, Rhegmatogenous Retinal Detachment
Interventions: Lamivudine 300 MG, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Retinal Detachment, Proliferative Vitreoretinopathy, Retinoschisis
Interventions: Triamcinolone, Bupivicaine Hydrochloride; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cataracts, Corneal Edema, Retinal Structural Change, Deposit and Degeneration, Visual Acuity Reduced Transiently
Interventions: Difluprednate ophthalmic emulsion 0.05%, Prednisolone acetate 1%; Drug
Lead sponsor: Edward J. Holland; Other
Eligibility: 21 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Edgewood, Kentucky • Lynbrook, New York • Mt. Pleasant, South Carolina

Conditions: Comparison of 3D Visualization and Microscope for VR Surgery
Interventions: Heads- Up Display Surgery; Device
Lead sponsor: MidAtlantic Retina; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Eye Diseases
Interventions: Next Generation Ophthalmic Irrigating Solution (NGOIS), BSS Plus; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Epiretinal Membrane, Macular Hole, Visually Significant Vitreous Floater, Vitreomacular Traction, Vitreous Hemorrhage, Proliferative Diabetic Retinopathy, Rhegmatogenous Retinal Detachment, Retained Lens Material in the Posterior Segment
Interventions: UNITY Vitreoretinal Cataract System (VCS), CONSTELLATION Vision System, Vitreoretinal ophthalmic surgery; Device · Procedure
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 8
States / cities: Scottsdale, Arizona • Laguna Hills, California • West Des Moines, Iowa + 5 more

Search by objective public record fields.

Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification

Macular Edema Incidence/Severity Reduction With Nevanac

Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma

Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery

Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery

PIONEER: Intraoperative and Perioperative OCT Study

Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%

Treatment of Macular Edema After Cataract Surgery with Subconjunctival Aflibercept

Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery

Preoperative and Intraoperative Factors Related to the Development of Ptosis After Retinal Surgery

Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD

The Relative Prevalence and Severity of Autonomic Nervous System Dysfunction

Computer-Assisted Rehabilitation Environment Training After Argus Retinal Prosthesis

Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema

Epiretinal Membrane and Pseudophakic Cystoid Macular Edema

Vitreous Surgery With Intraocular Assistance

DEXTENZA for the Treatment of Postoperative Pain and Inflammation Following Vitreo-retinal Surgery

DISCOVER Study: Microscope-integrated Intraoperative OCT Study

Lamivudine and Plasma Markers of Inflammation in Retinal Detachment

Postoperative Pain Control Following Vitreoretinal Surgery

Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery.

Comparision of Retinal Surgery by Three-dimensional Heads-up Display to the Standard Operating Microscope

Next Generation Ophthalmic Irrigating Solution Posterior Segment Study

UNITY VCS Vitreoretinal Surgery